Work

Design of REACH: Phase 3 Randomized, Double-Blind, Placebo-Controlled, 48-Week Study of the Efficacy and Safety of Losmapimod in FSHD (P6-8.007)

Year: 2023

Type: article

Study design: Study Protocol

Source: Neurology

DOI: 10.1212/wnl.0000000000201893

Authors: Alrabi Tawil, Jay Han, Leo Wang, John Vissing, Jeffrey Statland, Jennifer Shoskes, John Jiang

Institutions: University of Rochester Medicine, University of California, Irvine, University of Washington, University of Copenhagen, University of Kansas Medical Center, Fulcrum Therapeutics (United States)

Language: English

Topic: Muscle Physiology and Disorders

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4367304138

FWCI: 0.224

Cites:

Cited by: 3

Related to: 10